Skip to main content

Ovarian Cancer Clinical Trials

Review the ovarian cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 287

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Status: Active
Location: 10 locations
Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy for Folate Receptor Alpha Positive Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Location: 9 locations
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Status: Active
Location: 9 locations
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Status: Active
Location: 11 locations
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Status: Active
Location: 8 locations
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Status: Active
Location: 8 locations
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Status: Active
Location: 8 locations
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Status: Active
Location: 8 locations
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
Status: Active
Location: 8 locations
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Status: Active
Location: 9 locations
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Status: Active
Location: 8 locations
Minimally Invasive Surgery after Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Status: Active
Location: 8 locations
A Study of Isoquercetin for Reducing Blood Clot Formation Risk in Patients With Ovarian Cancer
Status: Active
Location: 7 locations
Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer
Status: Active
Location: 7 locations
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Status: Active
Location: 7 locations
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Status: Active
Location: 7 locations
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Status: Active
Location: 8 locations
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Status: Active
Location: 7 locations
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Status: Active
Location: 9 locations
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Status: Active
Location: 7 locations
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Status: Active
Location: 8 locations
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Status: Active
Location: 8 locations
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Status: Active
Location: 10 locations
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Status: Active
Location: 8 locations
Mirvetuximab Soravtansine and Olaparib for the Treatment of Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer with Positive Folate Receptor-Alpha Expression
Status: Active
Location: 6 locations